Please login to the form below

Not currently logged in
Email:
Password:

ZP2929

This page shows the latest ZP2929 news and features for those working in and with pharma, biotech and healthcare.

Boehringer switches diabetes candidate in Zealand collaboration

Boehringer switches diabetes candidate in Zealand collaboration

Boehringer switches diabetes candidate in Zealand collaboration. Will swap ZP2929 for another GLP-1 receptor agonist. ... Boehringer Ingelheim has decided to drop the diabetes and obesity drug candidate ZP2929 it has spent nearly three years developing

Latest news

  • Drug delivery

    Other deals of note were Boehringer Ingelheim's (BI) agreement with Zealand Pharma for rights to its ZP2929 - GLP1 receptor agonists against type 2 diabetes and obesity, further building the ... DPP-IV inhibitors (T2D) patent estate. Divestment. 609.

  • Boehringer and Zealand focus on diabetes

    Boehringer Ingelheim will obtain global development and commercialisation rights to ZP2929, Zealand Pharma's lead glucagon/GLP-1 dual agonist drug candidate. ... Zealand Pharma will be eligible to receive payments for ZP2929 and could receive additional

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics